East Sunshine Foresight Fund will make a “series of investments” of unspecified size in Enlyton, a Columbus, Ohio company developing novel imaging contrast agents.
January 9, 2018 -- East Sunshine Foresight Fund, the venture capital arm of Shenzhen’s HEC Pharm, will make a “series of investments” of unspecified size in Enlyton, a Columbus, Ohio company developing novel imaging contrast agents. Enlyton combines antibodies with contrast agents to produce tumor images that are more precise. Its lead product is ENL210, a bioengineered anti-TAG-72 (tumor-associated glycoprotein) antibody fragment labeled with iodine-123. The product targets a broad family of solid tumors known as adenocarcinomas.
